{"product_id":"cst-62294t","title":"CST,  62294T, RAR alpha (E6Z6K) Rabbit Monoclonal Antibody","description":"Monoclonal Antibody for studying RARA. Validated for Western Blotting,Immunoprecipitation,Chromatin IP. Available in 2 sizes. Highly specific and rigorously validated in-house, RAR alpha (E6Z6K) Rabbit Monoclonal Antibody (CST #62294) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nWestern Blotting: 1:1000\nImmunoprecipitation: 1:100\nChromatin IP: 1:50\n\u003cb\u003eStorage\u003c\/b\u003e\nSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg\/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.\n\u003cb\u003eProtocol\u003c\/b\u003e\nAvailable protocols: Western Blotting, Immunoprecipitation, Chromatin IP\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nRAR alpha (E6Z6K) Rabbit Monoclonal Antibody recognizes endogenous levels of total RARα protein. This antibody weakly detects RARγ when it is overexpressed.\nSpecies Reactivity: Human, Mouse, Monkey\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nMonoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu220 of human RARα protein.\n\u003cb\u003eBackground\u003c\/b\u003e\nRetinoids (vitamin A and its active retinoic acid derivatives) are non-steroid hormones that regulate cell proliferation, differentiation and apoptosis. Retinoic acid receptors (RARalpha, -beta and -gamma) and retinoid X receptors (RXRalpha, -beta and -gamma) are nuclear receptors that function as RAR-RXR heterodimers or RXR homodimers (1-2). In response to retinoid binding, these dimers control gene expression by binding to specific retinoic acid response elements, by recruiting cofactors and the transcriptional machinery, and by indirectly regulating chromatin structure. Finally, ligand binding and phosphorylation of RARalpha by JNK at Thr181, Ser445 and Ser461 controls the stability of RAR-RXR through the ubiquitin-proteasome pathway (3-4). At least four distinct genetic lesions affect RARalpha and result in acute promyelocytic leukemia (APL). The t(15;17) translocation that results in the PML-RARalpha fusion protein is responsible for more than 99% of APL cases, and the fusion protein inhibits PML-dependent apoptotic pathways in a dominant negative fashion. In addition PML-RARalpha inhibits transcription of retinoic acid target genes by recruiting co-repressors, attenuating myeloid differentiation (5-6).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nNR1B1; Nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long form; RAR; RAR-alpha; RARA; retinoic acid nuclear receptor alpha variant 1; retinoic acid nuclear receptor alpha variant 2; Retinoic acid receptor alpha; retinoic acid receptor, alpha; Retinoic acid receptor, alpha polypeptide\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H M Mk\nSENSITIVITY: Endogenous\nMW (kDa): 60\nSource\/Isotype: Rabbit IgG","brand":"CST","offers":[{"title":"Default Title","offer_id":46801028743337,"sku":"62294T","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-62294t","provider":"Iright","version":"1.0","type":"link"}